GlassScriptPhysician profile
Curtis A Phillippi
NPI 1235725102
$12,538.77
in general payments reported to CMS, 2019-2025
32 companies · $2,840 in 2025
The $2,840 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,548 · 2022: $2,694 · 2023: $2,676 · 2024: $2,781 · 2025: $2,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,022 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,022.26 |
| Education | $275.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,002.59 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,922.76 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,243.27 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $1,200.02 | 2021-2025 | Uptravi, Opsumit |
| Grifols USA, LLC | $785.18 | 2021-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $582.03 | 2021-2025 | Dupixent |
| Genzyme Corporation | $553.82 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $486.40 | 2021-2025 | Glassia, Cuvitru |
| Mylan Specialty L.P. | $393.09 | 2021-2024 | Yupelri |
| Amgen INC. | $336.42 | 2021-2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $260.72 | 2021-2024 | |
| Inogen, INC. | $237.77 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Viatris Specialty LLC | $213.30 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $190.28 | 2023-2025 | Winrevair |
| Insmed, INC. | $166.13 | 2025 | Arikayce, Brinsupri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $141.36 | 2025 | Ohtuvayre |
| Electromed, INC. | $108.53 | 2024 | Smartvest |
| Philips North America LLC | $104.03 | 2021-2023 | |
| Covis Pharma Gmbh | $93.08 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $85.93 | 2022 | |
| Sanofi-Aventis U.S. LLC | $84.99 | 2025 | |
| Mallinckrodt Hospital Products INC. | $69.91 | 2022-2024 | Acthar |
| Nabriva Therapeutics, Plc | $49.63 | 2021 | |
| Axsome Therapeutics, INC. | $44.00 | 2023-2024 | Sunosi |
| Pfizer INC. | $41.69 | 2023-2025 | |
| Baxter Healthcare | $30.37 | 2023 | Hillrom - Life 2000 Ventilation System |
| Pharming Healthcare, INC. | $26.19 | 2025 | Ruconest |
| Paratek Pharmaceuticals, INC. | $22.09 | 2022 | |
| Pulmonx Corporation | $18.93 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Abbvie INC. | $17.82 | 2021 | |
| Optinose US, INC. | $15.29 | 2024 | |
| Janssen Pharmaceuticals, INC | $11.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Phillippi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.